Angiogenesis in colorectal cancer: Prognostic and therapeutic implications

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 4, 2006, Pages 408-417

  Giatromanolaki, Alexandra ^a   Sivridis, Efthimios ^a   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

Author keywords

Angiogenesis; Angiogenic factors; Colorectal cancer; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CD31 ANTIGEN; CD34 ANTIGEN; COMBRETASTATIN; ENDOGLIN; ENDOSTATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; VON WILLEBRAND FACTOR; ANGIOGENIC PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DRUG POTENTIATION; ENDOTHELIUM CELL; FIBROBLAST; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PANCREAS CANCER; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; COLORECTAL TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; COLORECTAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; THYMIDINE PHOSPHORYLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746860827     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000221317.56731.4e     Document Type: Review

References (147)

1. Compton CC, Frederick LG. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54:295-308.
2. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracilbased adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797-1806.
3. Minsky BD. Adjuvant therapy of resectable rectal cancer. Cancer Treat Rev. 2002;28:181-188.
4. Anonymous. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980-987.
5. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
6. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395-3407.
7. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
8. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395-3407.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
10. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-3705.
11. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706-3712.
12. Hertig AT. Angiogenesis in the early human chorion and in the primary placenta of the Macaque monkey. Contrib Embryol. 1935;25:37-81.
13. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
14. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175-203.
15. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693.
16. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
17. Griffiths L, Stratford IJ. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer. 1997;76:689-693.
18. Chen CH, Poucher SM, Lu J, et al. Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol. 2004;2:33-43.
19. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309-325.
20. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
21. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38:1564-1579.
22. Duff SE, Li C, Garland JM, et al. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003;17:984-992.
23. Fox SB, Turley H, Cheale M, et al. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol. 2004;202:313-320.
24. Brekken RA, Thorpe PE. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 2001;21:4221-4229.
25. Saclarides TJ, Speziale NJ, Drab E, et al. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum. 1994;37:921-926.
26. Bossi P, Viale G, Lee AK, et al. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 1995;55:5049-5053.
27. Lindmark G, Gerdin B, Sundberg C, et al. Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol. 1996;14:461-466.
28. Takebayashi Y, Aklyama S, Yamada K, et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer. 1996;78:226-231.
29. Tomisaki S, Ohno S, Ichiyoshi Y, et al. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer. 1996;77(suppl):1722-1728.
30. Engel CJ, Bennett ST, Chambers AF, et al. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol. 1996;20:1260-1265.
31. Tanigawa N, Amaya H, Matsumura M, et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res. 1997;57:1043-1046.
32. Choi HJ, Hyun MS, Jung GJ, et al. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology. 1998;55:575-581.
33. Pavlopoulos PM, Konstantinidou AE, Agapitos E, et al. A morphometric study of neovascularization in colorectal carcinoma. Cancer. 1998;83:2067-2075.
34. Vermeulen PB, Van den Eynden GG, Huget P, et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer. 1999;79:316-322.
35. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, et al. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer. 1999;86:1421-14230.
36. Sternfeld T, Foss HD, Kruschewski M, et al. The prognostic significance of tumor vascularization in patients with localized colorectal cancer. Int J Colorectal Dis. 1999;14:272-276.
37. Pietra N, Sarli L, Caruana P, et al. Is tumour angiogenesis a prognostic factor in patients with colorectal cancer and no involved nodes? Eur J Surg. 2000;166:552-556.
38. Giatromanolaki A, Sivridis E, Minopoulos G, et al. Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. Clin Cancer Res. 2002;8:1185-1191.
39. Saad RS, Liu YL, Nathan G, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004;17:197-203.
40. Giatromanolaki A, Sivridis E, Koukourakis MI. Tumour angiogenesis: vascular growth and survival. APMIS. 2004;112:431-440.
41. Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to the human chromosome 6p21.3. Circulation. 1996;93:1493-1495.
42. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
43. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172:1535-1545.
44. Zheng S, Han MY, Xiao ZX, et al. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol. 2003;9:1227-1230.
45. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in nodenegative colon cancer. Arch Surg. 1997;132:541-546.
46. Tokunaga T, Oshika Y, Abe Y, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998;77:998-1002.
47. Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000;36:748-753.
48. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6:2803-2807.
49. Ochs AM, Wong L, Kakani V, et al. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer. 2004;4:262-267.
50. Werther K, Christensen IJ, Brunner N, et al. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol. 2000;26:657-662.
51. Akbulut H, Altuntas F, Akbulut KG, et al. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine. 2002;20:184-190.
52. Nakayama Y, Sako T, Shibao K, et al. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res. 2002;22:2437-2442.
53. Saharinen P, Petrova TV. Molecular regulation of lymphangiogenesis. Ann N Y Acad Sci. 2004;1014:76-87.
54. Parr C, Jiang WG. Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int J Oncol. 2003;23:533-539.
55. Onogawa S, Kitadai Y, Tanaka S, et al. Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Eur J Cancer. 2004;40:1604-1609.
56. Onogawa S, Kitadai Y, Tanaka S, et al. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 2004;95:32-39.
57. Maeda K, Yashiro M, Nishihara T, et al. Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum. Surg Today. 2003;33:736-739.
58. Bono P, Wasenius VM, Heikkila P, et al. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res. 2004;10:7144-7149.
59. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol. 2005;58:202-206.
60. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
61. Hachisuka T, Narikiyo M, Yamada Y, et al. High lymphatic vessel density correlates with overexpression of VEGF-C in gastric cancer. Oncol Rep. 2005;13:733-737.
62. Miyazono K, Okabe T, Urabe A, et al. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem. 1987;262:4098-4103.
63. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989;338:557-562.
64. Moghaddam A, Zhang HT, Fan TPD, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA. 1995;92:998-1002.
65. Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treatment Reviews. 1994;20:11-49.
66. Haraguchi M, Furukawa T, Sumizawa T, et al. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res. 1993;53:5680-5682.
67. Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 1996;88:1110-1117.
68. Matsumura M, Chiba Y, Lu C, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer. Cancer Lett. 1998;128:55-63.
69. Kaio E, Tanaka S, Kitadai Y, et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2003;64:61-73.
70. Matsuura T, Kuratate I, Teramachi K, et al. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas. Cancer Res. 1999;59:5037-5040.
71. Tokunaga Y, Hosogi H, Hoppou T, et al. Prognostic value of thymidine phosphorylase/platelet-derived endothelial cell growth factor in advanced colorectal cancer after surgery: evaluation with a new monoclonal antibody. Surgery. 2002;131:541-547.
72. Aoki T, Katsumata K, Tsuchida A, et al. Correlation between malignancy grade and p53 gene in relation to thymidine phosphorylase activity in colorectal cancer patients. Oncol Rep. 2002;9:1267-1271.
73. Saito S, Tsuno N, Nagawa H, et al. Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer. 2000;88:42-49.
74. Tsuji T, Sawai T, Yamashita H, et al. Platelet-derived endothelial cell growth factor expression is an independent prognostic factor in colorectal cancer patients after curative surgery. Eur J Surg Oncol. 2004;30:296-302.
75. Sivridis E, Giatromanolaki A, Koukourakis MI. Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity and oxidative stress. J Clin Pathol. 2005;58:1033-1038.
76. Hasegawa S, Seike K, Koda K, et al. Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. Oncol Rep. 2005;13:621-626.
77. Yasuno M, Mori T, Koike M, et al. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. Oncol Rep. 2005;13:405-412.
78. Yano S, Kazuno H, Sato T, et al. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase. Bioorg Med Chem. 2004;12:3443-3450.
79. Yano S, Kazuno H, Suzuki N, et al. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase. Bioorg Med Chem. 2004;12:3431-3441.
80. Uchimiya H, Furukawa T, Okamoto M, et al. Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose. Cancer Res. 2002;62:2834-2839.
81. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in nodenegative colon cancer. Arch Surg. 1997;132:541-46.
82. Berglund A, Molin D, Larsson A, et al. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol. 2002;13:1430-1437.
83. Akbulut H, Altuntas F, Akbulut KG, et al. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine. 2002;20:184-190.
84. Zeng Z, Weiser MR, D'Alessio M, et al. Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin Exp Metastasis. 2004;21:409-4017.
85. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995;1:147-154.
86. Ochiumi T, Tanaka S, Oka S, et al. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol. 2004;24:539-547.
87. Kaio E, Tanaka S, Oka S, et al. Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol. 2003;23:901-911.
88. Maeda K, Nishiguchi Y, Kang SM, et al. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep. 2001;8:763-766.
89. Tokunaga T, Nakamura M, Oshika Y, et al. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer. 1999;79:354-359.
90. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9:267-285.
91. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer. 2005;115:849-860.
92. Sis B, Sagol O, Kupelioglu A, et al. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract. 2004;200:379-387.
93. Tien YW, Lee PH, Hu RH, et al. The role of gelatinase in hepatic metastasis of colorectal cancer. Clin Cancer Res. 2003;9:4891-4896.
94. Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol. 2002;55:758-762.
95. Adachi Y, Yamamoto H, Itoh F, et al. Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer. 2001;95:290-294.
96. Curran S, Dundas SR, Buxton J, et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10:8229-8234.
97. Takeuchi T, Hisanaga M, Nagao M, et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res. 2004;10:5572-5579.
98. Holten-Andersen M, Christensen IJ, Nilbert M, et al. EORTC-Receptor and Biomarker Group. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. Eur J Cancer. 2004;40:64-72.
99. Chan CC, Menges M, Orzechowski HD, et al. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis. 2001;16:133-140.
100. Oberg A, Hoyhtya M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000;20:1085-1091.
101. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 2003;22:177-203.
102. Wahl ML, Kenan DJ, Gonzalez-Gronow M, et al. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem. 2005;96:242-261.
103. Abdollahi A, Hlatky L, Huber PE. Endostatin: the logic of antiangiogenic therapy. Drug Resist Update. 2005;8:59-74.
104. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs. 2004;13:1171-1182.
105. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027.
106. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996;93:14765-1470.
107. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731-3736.
108. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.
109. Koukourakis MI. Tumour angiogenesis and response to radiotherapy. Anticancer Res. 2001;21:4285-4300.
110. Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer. 2005;104:2517-2521.
111. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374-3378.
112. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61:2413-2419.
113. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60:5565-5570.
114. Grosjean J, Kiriakidis S, Reilly K, et al. Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem Biophys Res Commun. 2006;340:984-994.
115. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9:777-794.
116. Gorski DH, Mauceri HJ, Salloum RM, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998;58:5686-5689.
117. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998;394:287-291.
118. Koukourakis MI, Giatromanolaki A, Fountzilas G, et al. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res. 2000;6:381-9.
119. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Res. 2001;21:4301-9.
120. Frederick B, Gustafson D, Bianco C, et al. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:33-37.
121. Lu B, Shinohara ET, Edwards E, et al. The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy. Technol Cancer Res Treat. 2005;4:691-698.
122. Damiano V, Melisi D, Bianco C, et al. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res. 2005;11:5639-5344.
123. Bischof M, Abdollahi A, Gong P, et al. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys. 2004;60:1220-1232.
124. Bocci G, Danesi R, Marangoni G, et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol. 2004;498:9-18.
125. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671-80.
126. Stewart M, Turley H, Cook N, et al. The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology. 2003;2003:43:33-39.
127. Fox SB, Turley H, Cheale M, et al. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol. 2003;202:313-20.
128. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001;98:1904-13.
129. Price DJ, Miralem T, Jiang S, et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001;12:129-35.
130. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 2002;62:854-859.
131. Mross K, Drevs J, Muller M, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer. 2005;41:1291-1299.
132. Koukourakis MI, Giatromanolaki A, Simopoulos C, et al. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis. 2005;22:25-30.
133. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Including vasculature-related parameters (VRPs) in the Duke's staging system of colon cancer. Clin Cancer Res. 2005;11:8653-8660.
134. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217-227.
135. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000;60:3088-3095.
136. Giatromanolaki A, Sivridis E, Brekken R, et al. Tumour and Angiogenesis Research Group. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer. 2001;92:2569-2577.
137. Giatromanolaki A, Koukourakis MI, Stathopoulos GP, et al. Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res. 2000;12:33-41.
138. Brekken RA, Huang X, King SW, et al. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 1998;58:1952-1959.
139. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
140. Kindler HL, Friberg G, Skoog L, et al. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol. 2005;28:340-344.
141. Ouchi KF, Yanagisawa M, Sekiguchi F, et al. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol. 2006;57:693-702.
142. Braun AH, Stark K, Dirsch O, et al. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs. 2005;16:1099-1108.
143. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523-1530.
144. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995-4004.
145. Smith K, Gunaratnam L, Morley M, et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 2005;65:5221-5230.
146. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda). 2004;19:176-182.
147. Brown LM, Cowen RL, Debray C, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol. 2006;69:411-418.